Beijing, Chinese vaccine maker Sinovac has said that its Covid-19 vaccine candidate, CoronaVac, has been found to induce immune response in initial human trials.
No severe adverse events were reported in either the phase-1 or phase-2 trials, said the company on Saturday, while revealing preliminary results of the trials.